Henlius (02696.HK) announced that the Phase I clinical trial of HLX15, a biosimilar of Darzalex independently developed by the company, conducted in Chinese male healthy subjects has been successfully completed. The study results showed that the pharmacokinetic characteristics, safety, and immunogenicity of HLX15 were comparable to those of Darzalex from different sources. The study achieved all predetermined endpoints.

HLX15 is a biosimilar of Darzalex independently developed by the company for the treatment of multiple myeloma.